Table 1.

Clinical trials related to Myc overexpressing brain tumours.

Trial N°	Status	Study Title	Drug/Treatment	Condition	Sponsor	Collaborators
NCT03434262	Active, not recruiting	SJDAWN: St. Jude’s Children Research Hospital Phase-I study evaluating molecularly driven doublet therapies for children and young adults with recurrent brain tumors	Ribociclib/trametinib, ribociclib/sonidegib, ribociclib/gemcitabine	Brain tumors, including medulloblstoma, ependymoma, oligodendroglioma, glioblastoma (IDHwt and IDHmut), xanthoastrocytoma, neuroblastoma, medulloepithelioma, and embryonal tumors	St. Jude’s Children Research Hospital	Novartis Pharmaceuticals
NCT03224104	Completed	Study of TG02 in elderly newly diagnosed or adult relapsed patients with anaplastic astrocytoma or glioblastoma	TG02, TMZ, radiation	IDH1R132H-non mutated and MGMT-promoter-unmethylated anaplastic astrocytoma or GBM; IDH1R132H-non mutated and MGMT-promoter-methylated anaplastic astrocytoma or GBM	European Organization for Research and Treatment of Cancer (EORTC)	Tragara Pharmaceuticals
NCT02711137	Terminated	Open-label safety and tolerability study of INCB057643 in subjects with advanced malignancies	INCB057643, gemcitabine, paclitaxel, rucaparib, abiraterone, azacitidine, ruxolitinib	Solid tumors, including brain tumors and lymphoma	Incyte Corporation	Incyte Corporation